Haemophila B gene therapy breakthrough by UCL Sound published on 2011/12/19 18:11:08 +0000 For men with haemophilia B, the standard treatment is to have injections about twice a week so that the liver produces Factor IX for the blood to clot. Now for the first time, a gene therapy trial developed by Dr Amit Nathwani (UCL Cancer Institute) and colleagues in collaboration with St. Jude Children's Research Hospital in the U.S. has been able to reduce this treatment to a single injection for most of the patients in the study. Video: http://youtu.be/11maHFwC35s BBC News: http://bit.ly/sMPUHn New York Times: http://bit.ly/twldkJ UCL is consistently ranked as one of the world's top universities. Across all disciplines our faculties are known for their research-intensive approaches, academic excellence and engagement with global challenges. This is the basis of our world-renowned degree programmes. Visit us at www.ucl.ac.uk.